Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

James Pendleton

Pain Medicine Washington, DC Medical Doctor

NPI 1184155228 CMS profile 11305831

102 Irving St Nw, Washington, DC 20010

Open in the dashboard

General payments

$1,279

12 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Pendleton of Washington, DC is reported in the CMS Open Payments database as having received $1,279 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53 2
2023 General $552 4
2022 General $440 4
2021 General $234 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Pendleton
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to James Pendleton were reported at $53. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year James Pendleton Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $234 $299 $84–$899 $132
2022 $440 $335 $103–$1,149 $149
2023 $552 $376 $114–$1,228 $160
2024 $0 $387 $115–$1,173 $164
2025 $53 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $705 5 payments
  2. Boston Scientific Corporation $265 2 payments
  3. Merz Pharmaceuticals, LLC $234 2 payments
  4. Stryker Corporation $53 2 payments
  5. AbbVie, Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,200 11 payments
  2. Education $80 1 payment
Products named General payments · program years 2021–2025
  1. INTELLIS ADAPTIVESTIM $705 5 payments
  2. General - Pain Management $265 2 payments
  3. Xeomin $155 1 payment
  4. SPINEJACK $53 2 payments
  5. OPTABLATE $53 2 payments
  6. BOTOX $22 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

603

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$10,855

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

14.6%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 13 $2,483
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 64 $1,829
Lidocaine Generic 14 $952
Gabapentin Generic 57 $857
Duloxetine Hcl Generic 44 $684
Naloxone Hcl Generic 11 $596
Pregabalin Generic 51 $591
Methylprednisolone Generic 54 $530
Oxycodone Hcl Generic 40 $501
Meloxicam Generic 125 $366

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$27,842

Medicare's payments for the services billed

Medicare patients

108

Average age 72

Services billed

318

75 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Ischemic heart disease 31%
Chronic kidney disease 26%
Cancer 19%
Depression 19%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record